Valuation : Prothena Corporation plc

Market Cap 504M 434M 408M 372M 696M 47.68B 698M 4.83B 1.87B 24.42B 1.89B 1.85B 77.77B P/E 2026 *
89.3x
P/E 2027 * -10.6x
Enterprise Value 504M 434M 408M 372M 696M 47.68B 698M 4.83B 1.87B 24.42B 1.89B 1.85B 77.77B EV / Sales 2026 *
6.06x
EV / Sales 2027 * 20.7x
Free-Float
78.36%
Yield 2026 *
-
Yield 2027 * -
1 day+2.29%
1 week+5.25%
Current month+5.03%
1 month+14.45%
3 months+11.72%
6 months+2.40%
Current year+2.83%
1 week 9.26
Extreme 9.26
9.87
1 month 8.53
Extreme 8.53
9.87
Current year 7.73
Extreme 7.73
11.8
1 year 7.73
Extreme 7.73
11.8
3 years 4.32
Extreme 4.32
56.04
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Operating Officer 52 29/09/2021
Director TitleAgeSince
Chairman 76 20/12/2012
Director/Board Member 72 20/12/2012
Director/Board Member 63 20/12/2012
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 A Buy 27,000 0.0526%
8/20/26 A Buy 50,000 0.0955%
8/18/26 A Don -627,553 1.1987%
Change 5-day change 1-year change 3-year change Capi.($)
+2.29%+5.25%+14.85%-82.11% 504M
-0.38%-2.64%+42.69%+99.03% 67.98B
-2.71%-0.71%+34.08%+81.43% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
-1.42%-4.28%+31.24%+13.27% 25.74B
-1.11%+0.90%+23.12%-18.50% 20.09B
+1.15%-14.24%+219.82%+381.14% 17.16B
+0.20%-4.68%-6.41%+560.92% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average -0.16%+1.47%+39.45%+156.50% 27.96B
Weighted average by Cap. -0.81%+0.60%+36.93%+140.71%

Financials

2026 *2027 *
Net sales 83.16M 71.51M 67.26M 61.4M 115M 7.86B 115M 798M 308M 4.03B 312M 305M 12.83B 24.38M 20.96M 19.72M 18M 33.66M 2.31B 33.77M 234M 90.36M 1.18B 91.54M 89.54M 3.76B
Net income 6.22M 5.35M 5.03M 4.6M 8.6M 589M 8.62M 59.69M 23.07M 301M 23.37M 22.86M 960M -49.57M -42.63M -40.1M -36.6M -68.46M -4.69B -68.68M -475M -184M -2.4B -186M -182M -7.65B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
04/09/26 $9.820 +2.29% 383,928
03/09/26 $9.600 -0.88% 277,055
02/09/26 $9.685 +0.78% 341,055
01/09/26 $9.610 +2.78% 267,669
31/08/26 $9.350 +0.21% 335,149
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
9.820USD
Average target price
21.40USD
Spread / Average Target
+117.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!